Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.75 |
| ▸ | HTR6 | P50406 | 4/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.75 |
| ▸ | MAPT | P10636 | 4/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.75 |
| ▸ | EBP | Q15125 | 3/20 | 0.75 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.75 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.75 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.75 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.75 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.75 |
| ▸ | DRD3 | P35462 | 3/20 | 0.75 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.75 |
| ▸ | MEN1 | O00255 | 3/20 | 0.75 |
| ▸ | PGR | P06401 | 3/20 | 0.75 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.75 |
| ▸ | EGFR | P00533 | 2/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1394284 | 1.00 | ESR1 (0.75) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL8612317 | 0.92 | ESR1 (0.67) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL8612311 | 0.92 | ESR1 (0.67) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL8612318 | 0.92 | ESR1 (0.67) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL20224018 | 0.89 | ESR1 (0.78) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL12710314 | 0.87 | ESR1 (0.78) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL8842580 | 0.87 | ESR1 (0.64) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL8616725 | 0.87 | ESR1 (0.64) | ESR1HTR6KMT2AMAPTKCNH2 | |
| SCHEMBL8612298 | 0.87 | ESR1 (0.64) | ESR1HTR6KMT2AMAPTKCNH2 | |
| Enclomiphene SCHEMBL20594021 | 0.86 | ESR1 (1.00) | ESR1HTR6KMT2AMAPTKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3681478-B1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | ATOSSA THERAPEUTICS INC (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20240148675-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | ATOSSA THERAPEUTICS, INC. (US) | 2024-05-09 | — | — | US | disclosed |
| US-20200268690-A1 | TOPICAL COMPOSITIONS | ATOSSA THERAPEUTICS, INC. (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3681490-A1 | TOPICAL COMPOSITIONS | Atossa Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| EP-3681478-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | Atossa Therapeutics, Inc. (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20200215006-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | ATOSSA THERAPEUTICS, INC. (US) | 2020-07-09 | — | — | US | disclosed |
| EP-3656376-A1 | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM | Besins Healthcare Luxembourg SARL (LU) | 2020-05-27 | — | — | EP | disclosed |
| WO-2019051368-A1 | TOPICAL COMPOSITIONS | Atossa Genetics Inc. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051370-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | Atossa Genetics Inc. (US) | 2019-03-14 | — | — | WO | disclosed |
| US-20180049999-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF BREAST DISORDERS AND ESTROGEN-RELATED DISORDERS | ATOSSA THERAPEUTICS, INC. | 2018-02-22 | — | — | US | disclosed |
| EP-3283061-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF BREAST DISORDERS AND ESTROGEN-RELATED DISORDERS | Atossa Genetics Inc. (US) | 2018-02-21 | — | — | EP | disclosed |
| EP-3202420-A1 | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM | Besins Healthcare Luxembourg SARL (LU) | 2017-08-09 | — | — | EP | disclosed |
| WO-2016168021-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF BREAST DISORDERS AND ESTROGEN-RELATED DISORDERS | ATOSSA GENETICS, INC. (US) | 2016-10-20 | — | — | WO | disclosed |
| US-20120010245-A1 | TRANSDERMAL PHARMACEUTICAL COMPOSITIONS COMPRISING A SERM | BESINS HEALTHCARE LUXEMBOURG SARL | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200215006-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | CYP19A1, ESR1, SHBG | ESR1 2/4885HTR6 298/4885KMT2A 3491/4885 |
| US-20240148675-A1 | TOPICAL COMPOSITIONS AND METHODS FOR TREATMENT | CYP19A1, ESR1, SHBG | ESR1 2/4885HTR6 298/4885KMT2A 3491/4885 |
| US-20200268690-A1 | TOPICAL COMPOSITIONS | CYP19A1, HSD17B11, CYP17A1 | ESR1 11/4885HTR6 1657/4885KMT2A 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.